Actualités sur Health

15.06.2012 – 20:08
Bristol-Myers Squibb & Otsuka Pharmaceutical Europe Ltd.
Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
Paris (ots/PRNewswire) - Results Presented at 17th Congress of the European Hematology Association Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in Philadelphia ...
plus
15.06.2012 – 14:03
Janssen Pharmaceutica
Janssen Submits Additional Marketing Applications for ZYTIGA® in the European Union and in the U.S.
Beerse, Belgium And Raritan, New Jersey (ots/PRNewswire) - ? Simultaneous Submissions Based on Data from Pre-chemo Prostate Cancer Study Janssen-Cilag International NV announced today it has submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA(R); simultaneously, Janssen Research & ...
plus
15.06.2012 – 06:58
LifeWatch AG
EANS-Adhoc: The Board of Directors of LifeWatch rejects the candidates for its Board proposed by a group of shareholders (with document)
http://resources.euroadhoc.com/us/oRuLxHhe issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
14.06.2012 – 15:44
LEO Pharma
LEO Pharma Initiates Global Search for New Partners
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline. Corporate VP hopes to sign two or more new deals before the end of 2012. (Logo: http://photos.prnewswire.com/prnh/20120614/537969-a ) (Photo: http://photos.prnewswire.com/prnh/20120614/537969-b ) (Photo: ...
plus
09.06.2012 – 16:02
Janssen Pharmaceutica
Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies
Philadelphia (ots/PRNewswire) - Canagliflozin Provides Greater Reduction of A1C Levels in Adults with Type 2 Diabetes in 52-Week Head-to-Head Studies Compared to Sitagliptin and Glimepiride Janssen Research & Development, LLC (Janssen) presented results from five Phase 3 clinical studies evaluating canagliflozin in ...
plus
08.06.2012 – 12:39
PSI - EPSU
Algerian Trade Unionists in Critical Condition as Hunger Strike Enters Fifth Week
Geneva, Switzerland (ots/PRNewswire) - Government Ignores Deteriorating Health of Federal Justice Workers In protest against repeated human and trade union rights violations, nine union members, five women and four men, began an unlimited hunger strike on 6 May in Algiers, Algeria. Despite urgent requests for meetings, and daily reports on the workers' rapidly ...
plus
07.06.2012 – 17:38
LifeWatch AG
EANS-Adhoc: LifeWatch to launch world's first-of-its-kind healthcare solution Smartphone offering multiple embedded medical sensors and wellness-related applications as well as services (with document)
http://resources.euroadhoc.com/us/FuF7JANZ http://resources.euroadhoc.com/us/2dI7DlCg issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: ...
2 Documents
plus
07.06.2012 – 08:01
Hoya Corporation
Change of Management at HOYA Hill Optics in South Africa
Uithoorn, The Netherlands (ots/PRNewswire) - Hoya appointed Mr. Donald Currie as the Managing Director of HOYA Hill Optics following the acquisition of 100% of the shares in the company. Managing Director and founder of Hill Optics, Mr. Clifford Sher, will resign on June 30th 2012, while Mr. Donald Currie, who until recently held the position of Managing Director at Carl Zeiss Vision joined HOYA Hill Optics from June 1st. ...
plus
06.06.2012 – 10:03
UBM Live
2012 NuW Excellence Awards Judging Panel & Categories Announced
Frankfurt, Germany (ots/PRNewswire) - The categories and judging panel have been announced for the 7th edition of the Health ingredients, Natural ingredients & NuW awards programme, which recognizes exceptional innovations & talent within the nutrition + wellness industry. The focus of the health and wellness industry has switched gears. Instead of only taking an interest on health when a person's sick, consumers now seek ...
plus
06.06.2012 – 06:10
Bristol-Myers Squibb GmbH & Co. KGaA
ORENCIA® ? (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Paris (ots/PRNewswire) - ? - ORENCIA demonstrated comparable efficacy to HUMIRA based on a non-inferiority endpoint for ACR20 response at 1 year - Kinetics of response for ACR20, 50 and 70, and inhibition of radiographic progression were generally comparable over 12 months - AMPLE is the first head-to-head study in ...
plus
04.06.2012 – 18:05
LifeWatch AG
EANS-Adhoc: LifeWatch AG / The Board of Directors of LifeWatch rejects the demands put forth by a shareholder group and maintains its offer for one seat on the Board (with document)
http://resources.euroadhoc.com/us/POjmfdPf issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
29.05.2012 – 17:36
LifeWatch AG
EANS-Adhoc: LifeWatch completes major agreement for Home Sleep Testing with Sleep Management Solutions
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: ...
plus
29.05.2012 – 12:07
Occlutech GmbH
Occlutech Wins Dutch Supreme Court Ruling Against AGA/St Jude Medical
Jena, Germany (ots/PRNewswire) - Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable Supreme Court ruling from The Hague in The Netherlands in the on-going patent litigation with AGA/St Jude Medical. A first instance court ruling obtained in favour of Occlutech had been appealed by AGA in 2008, as had the ...
plus
28.05.2012 – 07:02
AstraZeneca GmbH
Data Presented at the European Atherosclerosis Society Congress Reinforces the Differentiating Benefits of CRESTOR[TM] in Comparison to Atorvastatin and Simvastatin
London (ots/PRNewswire) - THIS RELEASE IS INTENDED EXCLUSIVELY FOR EUROPEAN MEDIA Data presented today from the VOYAGER study demonstrate the benefits of aggressive statin therapy with CRESTOR(TM) (rosuvastatin) in comparison to atorvastatin and simvastatin in high risk patients. VOYAGER is an individual patient ...
plus
25.05.2012 – 10:22
Takeda Pharmaceutical Company Limited
Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
Osaka, Japan, And São Jerônimo, Brazil (ots/PRNewswire) - ? Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Multilab Industria e Comercio de Produtos Farmaceuticos Ltda. (Rio Grande do Sul, Brazil, "Multilab") today jointly announced that both parties have signed an agreement whereby Takeda Farmaceutica Brasil Ltda. (Sao Paulo, Brazil, "Takeda ...
plus
25.05.2012 – 06:59
LifeWatch AG
EANS-Adhoc: Invitation to the Ordinary General Meeting of Shareholders of LifeWatch Ltd., Neuhausen am Rheinfall on June 28, 2012 at 09:30 a.m. (doors open at 09:00 a.m.) at TECHNOPARK Zurich, Technoparkstrasse 1, 8005 Zurich (with document)
http://resources.euroadhoc.com/us/6PEp8eVI issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
24.05.2012 – 06:57
LifeWatch AG
EANS-Adhoc: LifeWatch Board declines request of change in control (with document)
http://resources.euroadhoc.com/us/ex4YiVpG issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss ...
plus
23.05.2012 – 10:31
Eisai Europe Limited
Once-Daily Epilepsy Treatment now Available in Sweden
Hatfield, England (ots/PRNewswire) - ? Reimbursement granted for Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited today announces the launch of Zebinix(R) (eslicarbazepine acetate) which will receive full reimbursement from the Swedish health authorities. Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset ...
plus
23.05.2012 – 10:02
Shire Pharmaceuticals Group Plc
Phase 3 Study Shows Efficacy is Maintained With lisdexamfetamine dimesylate (LDX) in Children and Adolescents With ADHD After at Least 6 Months of Treatment
Nyon, Switzerland (ots/PRNewswire) - Significantly lower proportion of subjects experiencing treatment failure whilst receiving LDX in the randomised withdrawal period, compared to those subjects receiving placebo.[1] Today, at the EUNETHYDIS 2nd International ADHD Conference, Shire AG , the global specialty ...
plus
18.05.2012 – 01:03
Eisai Europe Limited
Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
Hatfield, England (ots/PRNewswire) - Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's ...
plus
17.05.2012 – 13:32
ArQule, Inc. and Daiichi Sankyo, Co., Ltd.
Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology
Woburn, Massachusetts And Tokyo (ots/PRNewswire) - ArQule, Inc. and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line ...
plus
17.05.2012 – 08:02
EAASM
Patient Safety Group Renews Call for Urgent Action to Protect Patients From Harm
London (ots/PRNewswire) - The European Alliance for Access to Safe Medicines (EAASM) is calling for authorities to act now to clarify the conditions under which medicines can be used outside of their approved status. For example, the recent report from the US-based "CATT" study shows an increased risk of serious adverse events with the unlicensed (but widely-used) drug ...
plus
17.05.2012 – 00:03
Daiichi Sankyo Europe GmbH
World Hypertension Day 2012: Daiichi Sankyo Europe Announces Patient Website Dedicated to Hypertension
Munich (ots/PRNewswire) - **Not be used by UK media** To mark this year's World Hypertension Day, Daiichi Sankyo Europe has announced a website for patients offering more information about hypertension management and treatment. http://www.hypertensioncare.eu is now available to patients and physicians across Europe ...
plus
16.05.2012 – 19:55
Accuray Europe
Full Breadth and Depth of Accuray's Advanced, Personalized Radiation Treatment Capabilities Showcased at Estro 31
Sunnyvale, California (ots/PRNewswire) - Conference Presentations Highlighted Benefits of the CyberKnife(R) System's Motion Management and the TomoTherapy(R) System's Daily Image-Guidance Accuray Incorporated , the premier radiation oncology company, announced today that for the first time in Europe, at ESTRO 31 ...
plus
14.05.2012 – 14:02
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
Paris (ots/PRNewswire) - - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] today announced that the company will present 18 abstracts on abatacept ...
plus
14.05.2012 – 10:35
Turkcell
Turkcell's "People Without Boundaries" Initiative in Action
Istanbul, Turkey (ots/PRNewswire) - Turkcell , the leading communications and technology company in Turkey, has united all of its services and projects aimed at facilitating the lives of disabled citizens' and their participation in daily life under the "People Without Boundaries" roof in line with its vision of using technology to provide equal opportunities to all segments of society. Turkcell's services without ...
plus
10.05.2012 – 11:33
Fi Conferences
Innovations in Sports Nutrition : 29-30 May 2012 - Radisson Blu Portman Hotel, London
London (ots/PRNewswire) - http://www.fi-sportsnutrition.com Traditionally, sports nutrition products have been focused towards elite level athletes but the market is being transformed by the emergence of regular consumers who are not always interested in sports yet recognise the role that nutrition can play in helping their general health and wellness. With the active ...
plus
10.05.2012 – 06:57
LifeWatch AG
EANS-Adhoc: LifeWatch to announce positive results for first quarter 2012 (with document)
http://resources.euroadhoc.com/us/xB7woU7B http://resources.euroadhoc.com/us/3qJFtaGQ issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 ...
2 Documents
plus
02.05.2012 – 18:07
LifeWatch AG
EANS-Adhoc: LifeWatch contracts with an additional 41 Payors for ACT and Home Sleep Testing in Q1 2012 (with document)
http://resources.euroadhoc.com/us/LZrurKZz issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Un document
plus
30.04.2012 – 19:07
LifeWatch AG
EANS-Adhoc: LifeWatch AG publishes Annual Report 2011
issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss Exchange language: English ...
plus

Précédent53545556575859606162Suivant